Announcements Trials
Browse Landscape

Phase

Phase NA 13Phase 2 7Phase 3 4Phase 4 3Phase 1/2 2Phase 1 2Phase 2/3 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Breast Neoplasms 1128Carcinoma, Non-Small-Cell Lung 718Neoplasms 545Prostatic Neoplasms 502Colorectal Neoplasms 438Multiple Myeloma 336Lung Neoplasms 309Neoplasm Metastasis 288Leukemia, Myeloid, Acute 263Stomach Neoplasms 248Carcinoma, Hepatocellular 245Ovarian Neoplasms 225Rectal Neoplasms 211Colonic Neoplasms 204Lymphoma, Follicular 200Lymphoma 199Leukemia 190Uterine Cervical Neoplasms 181Head and Neck Neoplasms 174Pancreatic Neoplasms 171Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Recurrence 161Melanoma 158Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Squamous Cell Carcinoma of Head and Neck 147Pain 141Urinary Bladder Neoplasms 139Brain Neoplasms 133

Interventions

telaprevir 1peginterferon alfa-2a 1hepatitis C immune globulin, human 1elbasvir-grazoprevir drug combination 1Ribavirin 1Introns 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Hepatitis C × Clear all
NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated
1 enrolled 3 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

NCT04546802 2020-09-14

HATCHeT

Bayside Health

Phase 3 Withdrawn
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular

NCT01804829 2017-03-15

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Biotest Pharmaceuticals Corporation

Phase 3 Completed
80 enrolled
Gastrointestinal

Hepatitis, Viral, Human, Hepatitis C, Carcinoma, Hepatocellular, Liver Cirrhosis, Virus Diseases

NCT00273247 2006-01-09

Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis

National Cancer Institute, Milan

Phase 3 Completed
150 enrolled
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Liver Cirrhosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡